[go: up one dir, main page]

WO2003049699A3 - Novel monofunctional polyethylene glycol aldehydes - Google Patents

Novel monofunctional polyethylene glycol aldehydes Download PDF

Info

Publication number
WO2003049699A3
WO2003049699A3 PCT/US2002/039434 US0239434W WO03049699A3 WO 2003049699 A3 WO2003049699 A3 WO 2003049699A3 US 0239434 W US0239434 W US 0239434W WO 03049699 A3 WO03049699 A3 WO 03049699A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyethylene glycol
monofunctional polyethylene
aldehydes
novel monofunctional
novel
Prior art date
Application number
PCT/US2002/039434
Other languages
French (fr)
Other versions
WO2003049699A2 (en
Inventor
Perry Rosen
Kwang Nho
Original Assignee
Sun Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2001-0078244A external-priority patent/KR100488351B1/en
Application filed by Sun Bio Inc filed Critical Sun Bio Inc
Priority to AU2002357806A priority Critical patent/AU2002357806A1/en
Priority to EP02792347A priority patent/EP1507755A4/en
Publication of WO2003049699A2 publication Critical patent/WO2003049699A2/en
Publication of WO2003049699A3 publication Critical patent/WO2003049699A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/324—Polymers modified by chemical after-treatment with inorganic compounds containing oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Novel monofunctional polyethylene glycol aldehyde for pegylating therapeutically active proteins to produce pegylated protein conjugates which retain a substantial portion of their therapeutic activity and are less immunogenic than the protein from which the conjugate is derived and a new synthesis for preparing such aldehydes.
PCT/US2002/039434 2001-12-11 2002-12-09 Novel monofunctional polyethylene glycol aldehydes WO2003049699A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002357806A AU2002357806A1 (en) 2001-12-11 2002-12-09 Novel monofunctional polyethylene glycol aldehydes
EP02792347A EP1507755A4 (en) 2001-12-11 2002-12-09 Novel monofunctional polyethylene glycol aldehydes

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR10-2001-0078244A KR100488351B1 (en) 2001-12-11 2001-12-11 Novel polyethylene glycol-propionaldehyde derivatives
KR10-2001-0078244 2001-12-11
US34845202P 2002-01-16 2002-01-16
US60/348,452 2002-01-16
US38150302P 2002-05-17 2002-05-17
US60/381,503 2002-05-17
US40774102P 2002-09-03 2002-09-03
US60/407,741 2002-09-03

Publications (2)

Publication Number Publication Date
WO2003049699A2 WO2003049699A2 (en) 2003-06-19
WO2003049699A3 true WO2003049699A3 (en) 2004-12-29

Family

ID=27483540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039434 WO2003049699A2 (en) 2001-12-11 2002-12-09 Novel monofunctional polyethylene glycol aldehydes

Country Status (3)

Country Link
EP (1) EP1507755A4 (en)
AU (1) AU2002357806A1 (en)
WO (1) WO2003049699A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526151A (en) 2002-01-18 2005-09-02 バイオゲン アイデック エムエー インク． Polyalkylene glycols having moieties for the binding of biologically active compounds
CN1671769B (en) 2002-07-24 2010-05-12 弗·哈夫曼-拉罗切有限公司 Polyethylene glycol aldehyde derivatives
KR100974843B1 (en) 2002-09-09 2010-08-11 넥타르 테라퓨틱스 Water Soluble Polymer Alkanal
KR101162908B1 (en) * 2002-12-26 2012-07-06 마운틴 뷰 파마슈티컬즈, 인크. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
GEP20084486B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
KR101128320B1 (en) * 2003-05-23 2012-04-12 넥타르 테라퓨틱스 Peg derivatives having an amidocarbonate linkage
EP1951749A2 (en) * 2005-05-12 2008-08-06 Zymogenetics, Inc. Methods of using phhla2 to co-stimulate t-cells
FR2920777B1 (en) * 2007-09-11 2009-11-27 Centre Nat Rech Scient PROCESS FOR PREPARING THERMOSENSITIVE PROPYLENE POLY (PROPYLENE OXIDE) POLY (OXIDE) DERIVATIVES USEFUL FOR FUNCTIONALIZING CHITOSAN
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2070951A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
JP5480257B2 (en) * 2008-07-14 2014-04-23 バイオコン リミテッド Method for the synthesis of substantially monodisperse oligomer mixtures

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135683A (en) * 1991-03-28 1992-08-04 Arco Chemical Technology, L.P. Process for producing a deprotected alkoxylated polyol
WO2002059179A2 (en) * 2000-12-18 2002-08-01 Shearwater Corporation Synthesis of high molecular weight non-peptidic polymer derivatives
WO2003044056A2 (en) * 2001-11-20 2003-05-30 Pharmacia Corporation Chemically-modified human growth hormone conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
AU1325400A (en) * 1998-10-26 2000-05-15 University Of Utah Research Foundation Method for preparation of polyethylene glycol aldehyde derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135683A (en) * 1991-03-28 1992-08-04 Arco Chemical Technology, L.P. Process for producing a deprotected alkoxylated polyol
WO2002059179A2 (en) * 2000-12-18 2002-08-01 Shearwater Corporation Synthesis of high molecular weight non-peptidic polymer derivatives
WO2003044056A2 (en) * 2001-11-20 2003-05-30 Pharmacia Corporation Chemically-modified human growth hormone conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1507755A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein

Also Published As

Publication number Publication date
AU2002357806A1 (en) 2003-06-23
EP1507755A4 (en) 2006-05-17
WO2003049699A2 (en) 2003-06-19
AU2002357806A8 (en) 2003-06-23
EP1507755A2 (en) 2005-02-23

Similar Documents

Publication Publication Date Title
AU2022268401B2 (en) Conjugates of an IL-2 moiety and a polymer
WO2003049699A3 (en) Novel monofunctional polyethylene glycol aldehydes
WO2005097202A3 (en) Use of serum albumin binding peptides conjugates for the preparation of a medicament
WO2002026265A3 (en) Pegylated interleukin-10
CA2063886A1 (en) Polyethylene protein conjugates
ATE252601T1 (en) LONG-ACTING INSULINOTROPE PEPTIDES
CY1106886T1 (en) NEUBLASTIN POLYMER COGNITION PRODUCTS AND METHODS OF USE
IL145620A0 (en) A polypeptide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
WO2006024953A3 (en) Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
WO2004069176A3 (en) Polymer conjugates of mutated neublastin
EP1452543A3 (en) RGD (ARG-GLY-ASP) coupled to (neuro)peptides
FI982689L (en) Use of 2-phenyl-1,2-benzoisoselenazol-3(2H)-one for the preparation of pharmaceutical preparations for the treatment of Alzheimer's disease
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
WO2001036656A3 (en) A complex between hyaluronic acid and a biomolecule and its use
CA2368767A1 (en) Protease resistant flint analogs
AU2002327514A1 (en) Application of peptide conjugates to alzheimer's disease
EP1329507A4 (en) ARTIFICIAL PROTEIN WITH IMMUNOGENICITY OF POTENTIALIZED EPITOPE
WO2002000822A3 (en) A NOVEL POLYPEPTIDE, A HUMAIN PROTEIN SYNTHESIS INITIATION FACTOR SUB-UNIT 2 β 16.5 AND THE POLYNUCLEOTIDE ENCODING THE POLYPEPTIDE
WO2001042423A3 (en) Compositions and methods for detecting stress-inducible proteins
IL152221A0 (en) A polypeptide containing an immunogenic portion of breast tumor protein and pharmaceutical compositions containing the same
WO2001075035A3 (en) A novel polypeptide, human peroxydase protein 9 and the polynucleotide encoding the polypeptide
WO2001075034A3 (en) A novel polypeptide, human peroxydase protein 15 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002792347

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002792347

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP